search
Back to results

Multi-modality Imaging in Acute Myocardial Infarction (MIAMI)

Primary Purpose

Acute Myocardial Infarction, STEMI, Coronary Artery Disease

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Coronary Angiography
Sponsored by
William Beaumont Hospitals
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Acute Myocardial Infarction focused on measuring Intra Venous Ultrasound (IVUS), Fractional Flow Reserve (FFR), Optical Coherence Tomography (OCT), Acute Myocardial Infarction, Coronary Artery Disease (CAD), Angiography

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

All patients with ST-elevation acute myocardial infarction (STEMI) and age > 18 years who meet all of the following criteria:

  • Successful primary Percutaneous Intervention (PCI) of the Infarcted Related Artery (IRA) defined as final stenosis < 30%, Thrombolysis In Myocardial Infarction (TIMI) 3 flow
  • At least 1 non-IRA with diameter stenosis ≥ 50% and reference vessel diameter > 2mm
  • None of the exclusion criteria

Exclusion Criteria:

Patients will be excluded if any of the following are present:

  • Cardiogenic shock that persists > 24 hours after primary PCI
  • Diffuse disease in non-IRA that precludes successful stenting
  • Estimated Glomerular Filtration Rate (eGFR) < 30 cc/min/1.73 m2 after hydration or optimization of Congestive Heart Failure (CHF) for cardiac death
  • eGFR <60 cc/min/1.73 m2, will be in the MIAMI study for invasive imaging treatment group/cohort but will not get the coronary CCTA
  • eGFR < 60 cc/min/1.73 m2, for coronary CCTA
  • Active bleeding as defined as a fall in hemoglobin (HGB) concentration > 3 g/dL within 24 hours requiring blood transfusion, vasopressors to maintain Systolic BP > 100mmhg, or emergency surgical, endovascular, or endoscopic intervention.
  • Mechanical complication of MI such as severe Mitral-Valve Regurgitation (MR), Ventricular Septal Defect (VSD) or pulmonary edema
  • Uncontrolled Ventricular Tachycardia (VT) after primary PCI
  • Inability to provide informed consent
  • Ventilator-dependent respiratory failure
  • Only non-IRA is a chronic total occlusion
  • Non-IRA is in a Saphenous Vein Graft (SVG) or arterial graft
  • Non-IRA is in the left main, ostial Left Anterior Descending (LAD), or ostial Left circumflex (LCX)
  • Non-IRA includes a bifurcation with side branch > 2mm, medina 1-1-1
  • Need for multivessel primary PCI during the index procedure

Sites / Locations

  • William Beamont Hospital

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Angiography to Assess Vulnerable Plaque

Arm Description

In order to characterize plaque a repeat Coronary Angiography within 2 to 40 days will be done to assess vulnerable plaque features such as plaque tears, plaque thickness, plaque volume, and lipid content in plaque) in heart arteries in patients who have suffered a recent acute heart attack, and who have blockages >50% in one or more of the other arteries in the heart.

Outcomes

Primary Outcome Measures

Prevalence of hemodynamically-significant stenosis and "vulnerable" plaque in non-infarct-related coronary arteries in STEMI patients as measured during cardiac cath
2-40 days after the first cardiac catheterization procedure, depending on the urgency to evaluate the other arteries and the stability of the patient after the first procedure. Repeat cardiac catheterization for Data Analysis Stenosis severity (using angiographic criteria defined as Diameter Stenosis (DS) > 70% and DS > 50%;
Prevalence of hemodynamically-significant stenosis and "vulnerable" plaque in non-infarct-related coronary arteries in STEMI patients as measured by IVUS
Stenosis severity will be measured by IVUS criteria defined as minimal lumen cross sectional area (mCSA) < 4mm2, mCSA < 2.5mm2, plaque volume; and vulnerable plaque by IVUS-fibrous cap thickness.
Prevalence of hemodynamically-significant stenosis and "vulnerable" plaque in non-infarct-related coronary arteries in STEMI patients as measured by FFR
cardiac catheterization with FFR criteria defined as FFR < 0.80;
Prevalence of hemodynamically-significant stenosis and "vulnerable" plaque in non-infarct-related coronary arteries in STEMI patients as measured by OCT
Vulnerable plaque characteristics will be measured by OCT criteria - plaque ulceration, erosion, thrombus, fibrous cap thickness
Prevalence of hemodynamically-significant stenosis in non-infarct-related coronary arteries in STEMI patients as measured by CCTA
Stenosis severity will be measured by CCTA criteria-Diameter Stenosis >70%
Prevalence of hemodynamically-significant stenosis and "vulnerable" plaque in non-infarct-related coronary arteries in STEMI patients as measured by NIRS
Vulnerable plaque characteristics will be measure by NIRS criteria - Lipid Core Burden Index (LCBI) - 4mm > 300, Lipid Core Containing Plaque (LCP) distribution

Secondary Outcome Measures

Incidence of cardiac events at 1-year after STEMI.
Correlation between cardiovascular outcomes (MACE) at 1-year with measures of stenosis severity and presence of ≥ 1 feature of vulnerable plaque.
Correlation with coronary angiography with imagings findings and Coronary CT Angiography (CCTA) imaging findings.
In selected patients, Coronary CT Angiography (CCTA) will be performed within 40 days after the initial procedure that opens the artery . CCTA images will be evaluated for plaque characteristics, and correlated with the invasive findings.Fractional flow reserve via computed tomography (FFRCT), a non-invasive computed tomography method of measuring blood flow in the blocked arteries; will also be determined and correlated with invasive FFR.

Full Information

First Posted
August 15, 2016
Last Updated
April 8, 2019
Sponsor
William Beaumont Hospitals
search

1. Study Identification

Unique Protocol Identification Number
NCT02926755
Brief Title
Multi-modality Imaging in Acute Myocardial Infarction
Acronym
MIAMI
Official Title
Multi-modality Imaging in Acute Myocardial Infarction
Study Type
Interventional

2. Study Status

Record Verification Date
April 2019
Overall Recruitment Status
Completed
Study Start Date
January 20, 2016 (Actual)
Primary Completion Date
February 11, 2019 (Actual)
Study Completion Date
February 11, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
William Beaumont Hospitals

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The goal of this study is to use three (3) different imaging techniques:Fractional Flow Reserve (FFR) allows precise measurement of blood flow in the arteries to the heart, and is more reliable than pictures alone to determine the significance of blockages in the heart; Near Infra-Red Spectroscopy-Intravascular Ultrasound (NIRS IVUS) provides information about the amount of lipid and cholesterol in the plaque, and plaque volume; and Optical Coherence Tomography (OCT) allows physicians to assess tears in the surface of plaque and plaque thickness; to evaluate high risk non-infarct-related coronary lesion in patients who have suffered a recent heart attack, underwent successful opening of the artery with a stent, and have blockages greater than or equal to 50% in one or more of the other arteries to the heart; and to correlate this findings with cardiovascular outcomes at 1 year.
Detailed Description
This is a prospective, open-label, single center registry. The study is designed to characterize plaque (i.e., assess vulnerable plaque features such as plaque tears, plaque thickness, plaque volume, and lipid content in plaque) in heart arteries in patients who have suffered a recent acute heart attack, and who have blockages >50% in one or more of the other arteries in the heart. The procedure to do this will not be the same procedure that was done to open the artery that caused the heart attack, but will be scheduled 2-40 days after the first procedure, depending on the urgency to evaluate the other arteries and the stability of the patient after the first procedure. The study will specifically evaluate the plaque characteristics in the arteries that didn't cause the heart attack, to see if these arteries have vulnerable plaque and is at risk for future heart attacks. If FFR shows abnormal blood flow, these arteries will be treated with stents. All patients will be followed for 12 months after the second catheterization. The purpose of the study is to determine how commonly vulnerable plaques are identified in patients with acute heart attacks, and how often these lead to future cardiac problems. Identification of plaque features that lead to future problems may allow the development of new medications and devices to prevent future heart attacks and death. These same plaque features are also thought to be operative in patients with blockages in the arteries to the brain, so this study may have important implications for stroke prevention as well. All patients will be considered eligible for participation if they had a recent acute heart attack resulting from complete occlusion of an artery to the heart, if the stent procedure to open the artery was successful, and if they have blockages > 50% in at least one other major heart artery. Patients will not be eligible for participation if they are too unstable with regard to heart, lung, brain, or kidney function, or if they have previous bypasses to the heart. In selected patients, Coronary CT Angiography (CCTA) will be performed after the initial procedure to open the artery within 40 days. CCTA images will be evaluated for plaque characteristics, and correlated with the invasive findings.Fractional flow reserve via computed tomography (FFRCT), a non-invasive computed tomography method of measuring blood flow in the blocked arteries; will also be determined and correlated with invasive FFR. The standard portion of the procedure includes the angiogram (X-ray pictures of the arteries), FFR (measurement of blood flow in the artery), IVUS and/or OCT (to assess the diameter of the artery and the size of the stent), medications, and all office visits. The research portion of the study requires all imaging studies be performed (NIRS IVUS, OCT, FFR) rather than just one or two of these imaging studies, and the CCTA.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Myocardial Infarction, STEMI, Coronary Artery Disease, Atherosclerotic Plaque Disruption With Thrombosis of Artery
Keywords
Intra Venous Ultrasound (IVUS), Fractional Flow Reserve (FFR), Optical Coherence Tomography (OCT), Acute Myocardial Infarction, Coronary Artery Disease (CAD), Angiography

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
62 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Angiography to Assess Vulnerable Plaque
Arm Type
Experimental
Arm Description
In order to characterize plaque a repeat Coronary Angiography within 2 to 40 days will be done to assess vulnerable plaque features such as plaque tears, plaque thickness, plaque volume, and lipid content in plaque) in heart arteries in patients who have suffered a recent acute heart attack, and who have blockages >50% in one or more of the other arteries in the heart.
Intervention Type
Procedure
Intervention Name(s)
Coronary Angiography
Intervention Description
Coronary angiography which includes fractional flow reserve (FFR),that allows precise measurement of blood flow in the arteries to the heart; the Near Infra-Red Spectroscopy-Intravascular Ultrasound (NIRS IVUS) provides information about the amount of lipid and cholesterol in the plaque, and plaque volume;the Optical Coherence Tomography (OCT) allows physicians to assess tears in the surface of plaque and plaque thickness; and Coronary CT Angiography (CCTA) to evaluate plaque characteristics, and correlate with the invasive findings. The research portion of the study requires all imaging studies be performed (NIRS, IVUS, OCT, FFR) during coronary angiography, rather than just one or two of these imaging studies, and the CCTA.
Primary Outcome Measure Information:
Title
Prevalence of hemodynamically-significant stenosis and "vulnerable" plaque in non-infarct-related coronary arteries in STEMI patients as measured during cardiac cath
Description
2-40 days after the first cardiac catheterization procedure, depending on the urgency to evaluate the other arteries and the stability of the patient after the first procedure. Repeat cardiac catheterization for Data Analysis Stenosis severity (using angiographic criteria defined as Diameter Stenosis (DS) > 70% and DS > 50%;
Time Frame
40 Days
Title
Prevalence of hemodynamically-significant stenosis and "vulnerable" plaque in non-infarct-related coronary arteries in STEMI patients as measured by IVUS
Description
Stenosis severity will be measured by IVUS criteria defined as minimal lumen cross sectional area (mCSA) < 4mm2, mCSA < 2.5mm2, plaque volume; and vulnerable plaque by IVUS-fibrous cap thickness.
Time Frame
40 Days
Title
Prevalence of hemodynamically-significant stenosis and "vulnerable" plaque in non-infarct-related coronary arteries in STEMI patients as measured by FFR
Description
cardiac catheterization with FFR criteria defined as FFR < 0.80;
Time Frame
40 Days
Title
Prevalence of hemodynamically-significant stenosis and "vulnerable" plaque in non-infarct-related coronary arteries in STEMI patients as measured by OCT
Description
Vulnerable plaque characteristics will be measured by OCT criteria - plaque ulceration, erosion, thrombus, fibrous cap thickness
Time Frame
2 - 40 Days
Title
Prevalence of hemodynamically-significant stenosis in non-infarct-related coronary arteries in STEMI patients as measured by CCTA
Description
Stenosis severity will be measured by CCTA criteria-Diameter Stenosis >70%
Time Frame
2 - 40 Days
Title
Prevalence of hemodynamically-significant stenosis and "vulnerable" plaque in non-infarct-related coronary arteries in STEMI patients as measured by NIRS
Description
Vulnerable plaque characteristics will be measure by NIRS criteria - Lipid Core Burden Index (LCBI) - 4mm > 300, Lipid Core Containing Plaque (LCP) distribution
Time Frame
2 - 40 Days
Secondary Outcome Measure Information:
Title
Incidence of cardiac events at 1-year after STEMI.
Description
Correlation between cardiovascular outcomes (MACE) at 1-year with measures of stenosis severity and presence of ≥ 1 feature of vulnerable plaque.
Time Frame
1 Year
Title
Correlation with coronary angiography with imagings findings and Coronary CT Angiography (CCTA) imaging findings.
Description
In selected patients, Coronary CT Angiography (CCTA) will be performed within 40 days after the initial procedure that opens the artery . CCTA images will be evaluated for plaque characteristics, and correlated with the invasive findings.Fractional flow reserve via computed tomography (FFRCT), a non-invasive computed tomography method of measuring blood flow in the blocked arteries; will also be determined and correlated with invasive FFR.
Time Frame
40 Days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: All patients with ST-elevation acute myocardial infarction (STEMI) and age > 18 years who meet all of the following criteria: Successful primary Percutaneous Intervention (PCI) of the Infarcted Related Artery (IRA) defined as final stenosis < 30%, Thrombolysis In Myocardial Infarction (TIMI) 3 flow At least 1 non-IRA with diameter stenosis ≥ 50% and reference vessel diameter > 2mm None of the exclusion criteria Exclusion Criteria: Patients will be excluded if any of the following are present: Cardiogenic shock that persists > 24 hours after primary PCI Diffuse disease in non-IRA that precludes successful stenting Estimated Glomerular Filtration Rate (eGFR) < 30 cc/min/1.73 m2 after hydration or optimization of Congestive Heart Failure (CHF) for cardiac death eGFR <60 cc/min/1.73 m2, will be in the MIAMI study for invasive imaging treatment group/cohort but will not get the coronary CCTA eGFR < 60 cc/min/1.73 m2, for coronary CCTA Active bleeding as defined as a fall in hemoglobin (HGB) concentration > 3 g/dL within 24 hours requiring blood transfusion, vasopressors to maintain Systolic BP > 100mmhg, or emergency surgical, endovascular, or endoscopic intervention. Mechanical complication of MI such as severe Mitral-Valve Regurgitation (MR), Ventricular Septal Defect (VSD) or pulmonary edema Uncontrolled Ventricular Tachycardia (VT) after primary PCI Inability to provide informed consent Ventilator-dependent respiratory failure Only non-IRA is a chronic total occlusion Non-IRA is in a Saphenous Vein Graft (SVG) or arterial graft Non-IRA is in the left main, ostial Left Anterior Descending (LAD), or ostial Left circumflex (LCX) Non-IRA includes a bifurcation with side branch > 2mm, medina 1-1-1 Need for multivessel primary PCI during the index procedure
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Robert Safian, MD
Organizational Affiliation
William Beaumont Hospitals
Official's Role
Principal Investigator
Facility Information:
Facility Name
William Beamont Hospital
City
Royal Oak
State/Province
Michigan
ZIP/Postal Code
48073
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Multi-modality Imaging in Acute Myocardial Infarction

We'll reach out to this number within 24 hrs